Abstract
The protein kinase C (PKC) plays an important role in the activation and survival of B cells. The purpose of this study was to analyze the clinical significance of PKC-beta 2 protein expression in patients with diffuse large B-cell lymphoma (DLBCL). Tumors from 76 patients with DLBCL who received anthracycline-containing chemotherapy were examined for PKC-beta 2 protein expression by immunohistochemistry. Twenty-six cases (34%) were positive for PKC-beta 2 protein, and 50 (66%) were negative. Patients with PKC-beta-2-positive tumors showed a lower complete remission rate (31 vs 62%; P=0.015) and a lower 5-year disease-free survival (DFS) (30 vs 60%; P=0.03) than the PKC-beta-2-negative group. Overall survival (OS) was significantly lower in patients with the membranous staining pattern of PKC-beta 2 protein when compared to those with PKC-beta-2-negative tumors (14 vs 64%; P=0.005). In patients with low international prognostic index (IPI), those with tumors showing membrane expression of PKC-beta 2 had a significantly inferior DFS and OS (0 vs 79%, P=0.003; 25 vs 80%; P=0.01) compared to PKC-beta-2-negative tumors. In multivariate analysis for OS, the membrane staining of PKC-beta 2 is the strongest independent adverse prognostic factor (OR=3.4, P=0.011). Our results suggest that membrane expression of PKC-beta 2 protein on DLBCL predicts for poor survival, especially in patients with low IPI.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Biomarkers, Tumor / biosynthesis*
-
Biomarkers, Tumor / genetics
-
Cell Membrane / enzymology
-
Cell Membrane / genetics
-
Child
-
Cyclophosphamide / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Doxorubicin / analogs & derivatives
-
Female
-
Gene Expression Regulation, Enzymologic* / drug effects
-
Gene Expression Regulation, Enzymologic* / genetics
-
Gene Expression Regulation, Leukemic* / drug effects
-
Gene Expression Regulation, Leukemic* / genetics
-
Humans
-
Lymphoma, B-Cell / drug therapy
-
Lymphoma, B-Cell / enzymology*
-
Lymphoma, B-Cell / genetics
-
Lymphoma, B-Cell / mortality
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / enzymology*
-
Lymphoma, Large B-Cell, Diffuse / genetics
-
Lymphoma, Large B-Cell, Diffuse / mortality
-
Male
-
Middle Aged
-
Neoplasm Proteins / biosynthesis*
-
Neoplasm Proteins / genetics
-
Predictive Value of Tests
-
Prednisone / administration & dosage
-
Protein Kinase C / biosynthesis*
-
Protein Kinase C / genetics
-
Protein Kinase C beta
-
Retrospective Studies
-
Survival Rate
-
Vincristine / administration & dosage
Substances
-
Biomarkers, Tumor
-
Neoplasm Proteins
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Protein Kinase C
-
Protein Kinase C beta
-
Prednisone